GlassScriptPhysician profile
Katherine Beckwith
NPI 1518100239
$871.40
in general payments reported to CMS, 2019-2025
13 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.86 · 2021: $12.51 · 2022: $107 · 2023: $87.37 · 2024: $301 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $233.64 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $127.45 | 2022-2024 | |
| Insulet Corporation | $126.19 | 2019-2025 | Omnipod |
| Abbott Laboratories | $106.68 | 2024 | Freestyle Libre 3 |
| Biomarin Pharmaceutical INC. | $72.09 | 2024 | Voxzogo 1.2mg |
| Novo Nordisk INC | $40.20 | 2021-2025 | Sogroya |
| Tandem Diabetes Care, INC. | $38.40 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $30.14 | 2023 | Synthroid |
| Medtronic, INC. | $26.31 | 2025 | Minimed 780g |
| Pfizer INC. | $23.05 | 2024 | |
| Sequel Med Tech, LLC | $17.55 | 2025 | Twiist |
| Mannkind Corporation | $14.93 | 2023 | Afrezza |
| Alexion Pharmaceuticals, INC. | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Beckwith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.